Atossa Therapeutics (NASDAQ:ATOS) Given "Buy" Rating at HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $4.00 price objective on the stock. HC Wainwright's target price would suggest a potential upside of 159.74% from the stock's previous close.

Several other equities research analysts also recently weighed in on ATOS. StockNews.com downgraded Atossa Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, March 18th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Atossa Therapeutics in a report on Friday, January 12th.

Atossa Therapeutics Stock Performance

NASDAQ ATOS traded down $0.17 during trading hours on Tuesday, reaching $1.54. The stock had a trading volume of 1,713,842 shares, compared to its average volume of 1,357,200. Atossa Therapeutics has a 52-week low of $0.59 and a 52-week high of $2.31. The stock has a market cap of $192.96 million, a P/E ratio of -6.42 and a beta of 1.19. The stock has a fifty day moving average of $1.37 and a 200 day moving average of $0.98.

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last released its quarterly earnings data on Monday, April 1st. The company reported ($0.06) EPS for the quarter. On average, equities research analysts forecast that Atossa Therapeutics will post -0.28 EPS for the current year.

Insider Buying and Selling

In other news, Director Jonathan Finn acquired 25,000 shares of the business's stock in a transaction on Wednesday, April 10th. The stock was bought at an average price of $1.77 per share, with a total value of $44,250.00. Following the completion of the acquisition, the director now owns 25,000 shares of the company's stock, valued at $44,250. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 7.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Atossa Therapeutics

Hedge funds have recently bought and sold shares of the business. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Atossa Therapeutics during the 3rd quarter worth approximately $98,000. XTX Topco Ltd acquired a new position in Atossa Therapeutics during the second quarter worth $50,000. Two Sigma Securities LLC purchased a new position in Atossa Therapeutics during the second quarter valued at $32,000. Renaissance Technologies LLC grew its position in shares of Atossa Therapeutics by 14.7% in the second quarter. Renaissance Technologies LLC now owns 1,074,070 shares of the company's stock valued at $1,353,000 after purchasing an additional 138,000 shares during the period. Finally, LPL Financial LLC purchased a new stake in shares of Atossa Therapeutics during the second quarter worth about $59,000. Hedge funds and other institutional investors own 12.74% of the company's stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.